ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    cr39521
Previous Study | Return to List | Next Study

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD) (STAIRWAY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03038880
Recruitment Status : Completed
First Posted : February 1, 2017
Last Update Posted : October 18, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This is a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naive participants with nAMD. Only one eye will be chosen as the study eye.

Condition or disease Intervention/treatment Phase
Neovascularization, Choroidal Macular Degeneration, Age-Related Drug: Faricimab Drug: Ranibizumab Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Actual Study Start Date : January 27, 2017
Actual Primary Completion Date : January 12, 2018
Actual Study Completion Date : March 29, 2018


Arm Intervention/treatment
Experimental: Faricimab (Short interval)
Faricimab will be given via intravitreal (IVT) administration at a short interval duration during the 52 weeks treatment period.
Drug: Faricimab
Faricimab will be administered via IVT injections as specified during the treatment period.
Other Name: RO6867461; RG7716

Experimental: Faricimab (Long interval)
Faricimab will be given via IVT administration at a long interval duration during the 52 weeks treatment period.
Drug: Faricimab
Faricimab will be administered via IVT injections as specified during the treatment period.
Other Name: RO6867461; RG7716

Sham Comparator: Ranibizumab
Ranibizumab will be given via IVT administration during the 52 weeks treatment period.
Drug: Ranibizumab
Ranibizumab will be administered via IVT injections as specified during the treatment period.




Primary Outcome Measures :
  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40 Using the Early Treatment Diabetic Retinopathy Study (ETDRS)-Like Charts [ Time Frame: Baseline, Week 40 ]

Secondary Outcome Measures :
  1. Change From Baseline in BCVA at Protocol Specified Time-Points Using the ETDRS-Like Charts [ Time Frame: Baseline, up to Week 52 ]
  2. Percentage of Participants Gaining Greater Than or Equal to (>/=) 15, >/=10, >/=5, or >/=0 Letters From Baseline in BCVA at Protocol Specified Time-Points [ Time Frame: Baseline, up to Week 52 ]
  3. Percentage of Participants Avoiding Loss of >/=15, >/=10, >/=5, or >/=0 Letters From Baseline in BCVA at Protocol Specified Time-Points [ Time Frame: Baseline, up to Week 52 ]
  4. Percentage of Participants With BCVA of 20/40 or Better [ Time Frame: Baseline up to Week 52 ]
  5. Percentage of Participants With BCVA of 20/200 or Worse [ Time Frame: Baseline up to Week 52 ]
  6. Change From Baseline in Central Foveal Thickness (CFT) at Protocol Specified Time-Points [ Time Frame: Baseline, up to Week 52 ]
  7. Change From Baseline in Central Subfield Thickness (CST) at Protocol Specified Time-Points [ Time Frame: Baseline, up to Week 52 ]
  8. Percentage of Participants With Intraretinal Fluid, Subretinal Fluid, Cysts, or Pigment Epithelial Detachment [ Time Frame: Baseline, up to Week 52 ]
  9. Change From Baseline in Total Area of Choroidal Neovascularization (CNV) at Protocol Specified Time-Points [ Time Frame: Baseline, up to Week 52 ]
  10. Change From Baseline in Total Area of CNV Component at Protocol Specified Time-Points [ Time Frame: Baseline, up to Week 52 ]
  11. Change From Baseline in Total Area of Leakage at Protocol Specified Time-Points [ Time Frame: Baseline, up to Week 52 ]
  12. Percentage of Participants With Anti-Faricimab Antibodies [ Time Frame: Baseline up to Week 52 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Treatment-naive CNV secondary to AMD
  • Subfoveal or juxtafoveal CNV with a subfoveal component related to the CNV activity
  • Active CNV
  • BCVA letter score of 73 to 24 letters (inclusive)

Exclusion Criteria:

  • CNV due to causes other than AMD
  • Retinal pigment epithelial tear involving the macula
  • On fundus fluorescein angiography (FFA) subretinal hemorrhage, fibrosis or atrophy of >50% of the total lesion area and/or that involves the fovea
  • Cataract surgery within 3 months of baseline assessments
  • Uncontrolled blood pressure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03038880


  Show 33 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03038880     History of Changes
Other Study ID Numbers: CR39521
First Posted: February 1, 2017    Key Record Dates
Last Update Posted: October 18, 2018
Last Verified: October 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Macular Degeneration
Neovascularization, Pathologic
Wet Macular Degeneration
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
Eye Diseases
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Ranibizumab
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents